Nanotheranostics, a future remedy of neurological disorders

References

• Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine. 2008;2:137–140.
   Google Scholar
• Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064–1079.
   PubMed Web of Science ®Google Scholar
• Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052–1063.
   PubMed Web of Science ®Google Scholar
• Organization WH. Neurological disorders affect millions globally: WHO report. Brussels/Geneva: World Health Organization; 2007.
   Google Scholar
• Prince M, Wimo A, Guerchet M, et al. World Alzheimer report 2015—the global impact of dementia: an analysis of prevalence, incidence, cost and trends; 2015.
   Google Scholar
• Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiology. 2015;45:161–176.
   PubMed Web of Science ®Google Scholar
• McFaline-Figueroa JR, Lee EQ. Brain tumors. Am J Med. 2018;131:874–882.
   PubMed Web of Science ®Google Scholar
• Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncol. 2017;19:v1- v88.
   PubMed Web of Science ®Google Scholar
• Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1:102.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
   PubMed Web of Science ®Google Scholar
• Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine. 2005;1:101–109.
   PubMed Web of Science ®Google Scholar
• Bhojani MS, Van Dort M, Rehemtulla A, et al. Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm. 2010;7:1921–1929.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Mei L, Feng -S-S. Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine. 2014;9:1277–1280.
   PubMed Web of Science ®Google Scholar
• Delhaye C, Mahmoudi M, Waksman R. Hypothermia therapy: neurological and cardiac benefits. J Am Coll Cardiol. 2012;59:197–210.
   PubMed Web of Science ®Google Scholar
• Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9:277–291.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Omuro A. Current role of anti-angiogenic strategies for glioblastoma. Curr Treat Options Oncol. 2014;15:551–566.
   PubMed Web of Science ®Google Scholar
• Yoo J, Kim HS, Hwang DY. Stem cells as promising therapeutic options for neurological disorders. J Cell Biochem. 2013;114:743–753.
   PubMed Web of Science ®Google Scholar
• Pereira GC, Traughber M, Muzic RF. The role of imaging in radiation therapy planning: past, present, and future. Biomed Res Int. 2014;2014:9.
   Google Scholar
• Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–2663.
   PubMed Web of Science ®Google Scholar
• Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009;461:916.
   PubMed Web of Science ®Google Scholar
• Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014;55:2003–2011.
   PubMed Web of Science ®Google Scholar
• Zhu L, Ploessl K, Kung HF. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014;43:6683–6691.
   PubMed Web of Science ®Google Scholar
• Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193–207.
   PubMed Web of Science ®Google Scholar
• Kasban H, El-Bendary M, Salama D. A comparative study of medical imaging techniques. Int J Inf Sci Intell Syst. 2015;4:37–58.
   Google Scholar
• Grover VP, Tognarelli JM, Crossey MM, et al. Magnetic resonance imaging: principles and techniques: lessons for clinicians. J Clin Exp Hepatol. 2015;5:246–255.
   PubMed Web of Science ®Google Scholar
• Jain TK, Richey J, Strand M, et al. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials. 2008;29:4012–4021.
   PubMed Web of Science ®Google Scholar
• Blau R, Epshtein Y, Pisarevsky E, et al. Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins. Theranostics. 2018;8:3437.
   PubMed Web of Science ®Google Scholar
• Ladd ME, Bachert P, Meyerspeer M, et al. Pros and cons of ultra-high-field MRI/MRS for human application. Prog Nucl Magn Reson Spectrosc. 2018;109:1–50.
   PubMed Web of Science ®Google Scholar
• Louie A. Multimodality imaging probes: design and challenges. Chem Rev. 2010;110(5):3146–3195.
   PubMed Web of Science ®Google Scholar
• Lu F-M, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5:433.
   PubMed Web of Science ®Google Scholar
• Zhang S, Sun C, Zeng J, et al. Ambient aqueous synthesis of ultrasmall PEGylated Cu2− xSe nanoparticles as a multifunctional theranostic agent for multimodal imaging guided photothermal therapy of cancer. Adv Mater. 2016;28:8927–8936.
   PubMed Web of Science ®Google Scholar
• Miao Q, Xie C, Zhen X, et al. Molecular after glow imaging with bright, biodegradable polymer nanoparticles. Nat Biotechnol. 2017;35:1102.
   PubMed Web of Science ®Google Scholar
• Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci. 2001;24:719–725.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:320941.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733–1744.
   PubMed Web of Science ®Google Scholar
• Hajal C, Campisi M, Mattu C, et al. In vitro models of molecular and nano-particle transport across the blood-brain barrier. Biomicrofluidics. 2018;12:042213.
   PubMed Web of Science ®Google Scholar
• Xu S, Olenyuk BZ, Okamoto CT, et al. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65:121–138.
   PubMed Web of Science ®Google Scholar
• Schöttler S, Becker G, Winzen S, et al. Protein adsorption is required for stealth effect of poly (ethylene glycol)-and poly (phosphoester)-coated nanocarriers. Nat Nanotechnol. 2016;11:372.
   PubMed Web of Science ®Google Scholar
• Peng H, Liu X, Wang G, et al. Polymeric multifunctional nanomaterials for theranostics. J Mater Chem B. 2015;3:6856–6870.
   PubMed Web of Science ®Google Scholar
• Tang W-L, Tang W-H, Li S-D. Cancer theranostic applications of lipid-based nanoparticles. Drug Discov Today. 2018;23:1159–1166.
   Web of Science ®Google Scholar
• Wen C-J, Zhang L-W, Al-Suwayeh SA, et al. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine. 2012;7:1599.
   PubMed Web of Science ®Google Scholar
• Sonali SRP, Singh N, Sharma G, et al. Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. Drug Deliv. 2016;23:1261–1271.
   PubMed Web of Science ®Google Scholar
• Guo H, Chen W, Sun X, et al. Theranostic magnetoliposomes coated by carboxymethyl dextran with controlled release by low-frequency alternating magnetic field. Carbohydr Polym. 2015;118:209–217.
   PubMed Web of Science ®Google Scholar
• Shazeeb MS, Feula G, BogdanovJr A. Liposome‐encapsulated superoxide dismutase mimetic: theranostic potential of an MR detectable and neuroprotective agent. Contrast Media Mol Imaging. 2014;9:221–228.
   PubMed Web of Science ®Google Scholar
• Agulla J, Brea D, Campos F, et al. In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics. 2014;4:90–105.
   Web of Science ®Google Scholar
• Singh RP, Sharma G, Kumari L, et al. RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloids Surf B Biointerfaces. 2016;147:129–141.
   PubMed Web of Science ®Google Scholar
• Rajora M, Ding L, Valic M, et al. Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma. Chem Sci. 2017;8:5803.
   PubMed Web of Science ®Google Scholar
• Saesoo S, Sathornsumetee S, Anekwiang P, et al. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids Surf B Biointerfaces. 2018;161:497–507.
   PubMed Web of Science ®Google Scholar
• Bernal GM, LaRiviere MJ, Mansour N, et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2014;10:149–157.
   PubMed Web of Science ®Google Scholar
• Stephen ZR, Kievit FM, Veiseh O, et al. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors. ACS Nano. 2014;8:10383–10395.
   PubMed Web of Science ®Google Scholar
• Roy Chowdhury S, Mondal S, Muthuraj B, et al. Remarkably efficient blood–brain barrier crossing polyfluorene–chitosan nanoparticle selectively tweaks amyloid oligomer in cerebrospinal fluid and Aβ1–40. ACS Omega. 2018;3:8059–8066.
   PubMed Web of Science ®Google Scholar
• Su C-H, Tsai C-Y, Tomanek B, et al. Evaluation of blood–brain barrier-stealth nanocomposites for in situ glioblastoma theranostics applications. Nanoscale. 2016;8:7866–7870.
   PubMed Web of Science ®Google Scholar
• Zhang R, Li Y, Hu B, et al. Traceable nanoparticle delivery of small interfering RNA and retinoic acid with temporally release ability to control neural stem cell differentiation for alzheimer’s disease therapy. Adv Mater. 2016;28:6345–6352.
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Ji W, et al. Positively charged polyprodrug amphiphiles with enhanced drug loading and reactive oxygen species-responsive release ability for traceable synergistic therapy. J Am Chem Soc. 2018;140:4164–4171.
   PubMed Web of Science ®Google Scholar
• Dehvari K, Lin K-S. Synthesis, characterization and potential applications of multifunctional PEO-PPOPEO-magnetic drug delivery system. Curr Med Chem. 2012;19:5199–5204.
   PubMed Web of Science ®Google Scholar
• Skaat H, Corem-Slakmon E, Grinberg I, et al. Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils. Int J Nanomed. 2013;8:4063.
   PubMed Web of Science ®Google Scholar
• Gao X, Yue Q, Liu Y, et al. Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins. Theranostics. 2018;8:3126.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Javanzad S, Saleh T, et al. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10:321–332.
   PubMed Web of Science ®Google Scholar
• Patel T, Zhou J, Piepmeier JM, et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64:701–705.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu R, Ji W, et al. Delivery systems for theranostics in neurodegenerative diseases. Nano Res. 2018;10:5535–5555.
   Google Scholar
• Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv. 2010;7:1191–1207.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–522.
   PubMed Web of Science ®Google Scholar
• Vio V, Jose Marchant M, Araya E, et al. Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases. Curr Pharm Des. 2017;23:1916–1926.
   PubMed Web of Science ®Google Scholar
• Auzel F. Upconversion and anti-stokes processes with f and d ions in solids. Chem Rev. 2004;104:139–174.
   PubMed Web of Science ®Google Scholar
• Wu X, Chen G, Shen J, et al. Upconversion nanoparticles: a versatile solution to multiscale biological imaging. Bioconjugate Chem. 2014;26(2):166–175.
   PubMed Web of Science ®Google Scholar
• Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol. 2010;14(1):71–79.
   PubMed Web of Science ®Google Scholar
• Fang W, Wei Y. Upconversion nanoparticle as a theranostic agent for tumor imaging and therapy. J Innov Opt Health Sci. 2016;9:1630006.
   Web of Science ®Google Scholar
• Gamage N, Jing L, Worsham M, et al. Targeted theranostic approach for glioma using dendrimer-based curcumin nanoparticle. J Nanomed Nanotechnol. 2016;7:393.
   Google Scholar
• Vardharajula S, Ali SZ, Tiwari PM, et al. Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine. 2012;7:5361.
   PubMed Web of Science ®Google Scholar
• Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23:H217–H47.
   PubMed Web of Science ®Google Scholar
• Ruan S, He Q, Gao H. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale. 2015;7:9487–9496.
   PubMed Web of Science ®Google Scholar
• Fan C-H, Ting C-Y, Lin H-J, et al. SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials. 2013;34:3706–3715.
   PubMed Web of Science ®Google Scholar
• Sun L, Joh DY, Al-Zaki A, et al. Theranostic application of mixed gold and superparamagnetic iron oxide nanoparticle micelles in glioblastoma multiforme. J Biomed Nanotechnol. 2016;12:347–356.
   PubMed Web of Science ®Google Scholar
• Zhou J-E, Yu J, Gao L, et al. iNGR-modified liposomes for tumor vascular targeting and tumor tissue penetrating delivery in the treatment of glioblastoma. Mol Pharm. 2017;14:1811–1820.
   PubMedGoogle Scholar
• Ramachandran R, Junnuthula VR, Gowd GS, et al. Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. Sci Rep. 2017;7:43271.
   PubMed Web of Science ®Google Scholar
• Jing H, Weidensteiner C, Reichardt W, et al. Imaging and selective elimination of glioblastoma stem cells with theranostic near-infrared-labeled CD133-specific antibodies. Theranostics. 2016;6:862.
   PubMed Web of Science ®Google Scholar
• Sun C, Veiseh O, Gunn J, et al. In vivo MRI detection of gliomas by chlorotoxin‐conjugated superparamagnetic nanoprobes. Small. 2008;4:372–379.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
   PubMed Web of Science ®Google Scholar
• Potschka H. Targeting the brain–surmounting or by passing the blood–brain barrier. Drug Deliv. 2010;197:411–431.
   Google Scholar
• Du Z, Gao N, Guan Y, et al. Rational design of a “sense and treat” system to target amyloid aggregates related to Alzheimer’s disease. Nano Res. 2018;11:1987–1997.
   Web of Science ®Google Scholar
• Chen Q, Du Y, Zhang K, et al. Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer’s disease. ACS Nano. 2018;12:1321–1338.
   PubMed Web of Science ®Google Scholar
• Hu B, Dai F, Fan Z, et al. Nanotheranostics: congo Red/Rutin‐MNPs with enhanced magnetic resonance imaging and H2O2‐responsive therapy of Alzheimer’s disease in APPswe/PS1dE9 transgenic mice. Adv Mater. 2015;27:5499–5505.
   PubMed Web of Science ®Google Scholar
• Li M, Guan Y, Zhao A, et al. Using multifunctional peptide conjugated Au nanorods for monitoring β-amyloid aggregation and chemo-photothermal treatment of Alzheimer’s disease. Theranostics. 2017;7:2996–3006.
   Web of Science ®Google Scholar
• Cui Z, Bu W, Fan W, et al. Sensitive imaging and effective capture of Cu2+: towards highly efficient theranostics of Alzheimer’s disease. Biomaterials. 2016;104:158–167.
   PubMed Web of Science ®Google Scholar
• Costa PM, Bourgognon M, Wang JT, et al. Functionalised carbon nanotubes: from intracellular uptake and cell-related toxicity to systemic brain delivery. J Control Release. 2016;241:200–219.
   PubMed Web of Science ®Google Scholar
• Kafa H, Wang JT-W, Rubio N, et al. The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. Biomaterials. 2015;53:437–452.
   PubMed Web of Science ®Google Scholar
• Kafa H, Wang JT-W, Rubio N, et al. Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood–brain barrier in vitro and in vivo. J Control Release. 2016;225:217.
   PubMed Web of Science ®Google Scholar
• Wang JT-W, Rubio N, Kafa H, et al. Kinetics of functionalised carbon nanotube distribution in mouse brain after systemic injection: spatial to ultra-structural analyses. J Control Release. 2016;224:22–32.
   PubMed Web of Science ®Google Scholar
• Costa PM, Wang JT-W, Morfin J-F, et al. Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting Pittsburgh compound B (PiB)-Derived ligands. Nanotheranostics. 2018;2:168.
   PubMedGoogle Scholar
• Li Y, Xu D, Ho S-L, et al. A theranostic agent for in vivo near-infrared imaging of β-amyloid species and inhibition of β-amyloid aggregation. Biomaterials. 2016;94:84–92.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice. Biomaterials. 2014;35:456–465.
   PubMed Web of Science ®Google Scholar
• Ozansoy M, Başak AN. The central theme of Parkinson’s disease: α-synuclein. Mol Neurobiol. 2013;47:460–465.
   PubMed Web of Science ®Google Scholar
• Kubrusly RC, Mzp G, Vieira APB, et al. L‐DOPA supply to the neuro retina activates dopaminergic communication at the early stages of embryonic development. J Neurochem. 2003;86:45–54.
   PubMed Web of Science ®Google Scholar
• Reis RA, Ventura ALM, Kubrusly RC, et al. Dopaminergic signaling in the developing retina. Brain Res Rev. 2007;54:181–188.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3–14.
   PubMedGoogle Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670–1683.
   PubMed Web of Science ®Google Scholar
• McDonagh BH, Singh G, Hak S, et al. L‐DOPA‐coated manganese oxide nanoparticles as dual MRI contrast agents and drug‐delivery vehicles. Small. 2016;12:301–306.
   PubMed Web of Science ®Google Scholar
• Niu S, Zhang L-K, Zhang L, et al. Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson’s disease model. Theranostics. 2017;7:344.
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release. 2011;151:131–138.
   PubMed Web of Science ®Google Scholar
• Hu K, Shi Y, Jiang W, et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm. 2011;415:273–283.
   PubMed Web of Science ®Google Scholar
• Gupta AS. Nanomedicine approaches in vascular disease: a review. Nanomedicine. 2011;7:763–779.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Korngold E, Weissleder R, et al. A light‐activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010;6:2041–2049.
   PubMed Web of Science ®Google Scholar
• Myerson JW, He L, Allen JS, et al. Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology. 2014;25:395101.
   PubMed Web of Science ®Google Scholar
• Sun Z, Huang P, Tong G, et al. VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle. Nanoscale. 2013;5:6857–6866.
   PubMed Web of Science ®Google Scholar
• Agyare EK, Jaruszewski KM, Curran GL, et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014;185:121–129.
   PubMed Web of Science ®Google Scholar
• Liu H, Jablonska A, Li Y, et al. Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke. Theranostics. 2016;6:1588.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Xia J, et al. Neuronal PirB upregulated in cerebral ischemia acts as an attractive theranostic target for ischemic stroke. J Am Heart Assoc. 2018;7:e007197.
   PubMed Web of Science ®Google Scholar